Novo Nordisk’s obesity treatment candidate CagriSema has shown mixed results in late-stage trials, sparking concerns that it may not live up to investors’ expectations. The drug was compared to Eli Lilly’s Zepbound in safety and efficacy trials. While CagriSema led to a 20% weight loss in patients over 68 weeks, similar to Zepbound, the rate of weight loss slowed down significantly towards the end of the trial period, casting doubts on its potential for long-term success.
Source: https://www.statnews.com/2025/06/22/novo-nordisk-cagrisema-weight-loss-drug-comparison-eli-lilly-zepbound-investors-disappointed